Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
Tango Therapeutics (NASDAQ: TNGX) announced the acceptance of five abstracts for poster presentation at the AACR Annual Meeting 2025 in Chicago. The presentations will showcase preclinical data focusing on their PRMT5 inhibitor programs, particularly TNG456 and TNG462, designed for treating MTAP-deleted cancers.
The research highlights include evaluation of CNS drug penetration, brain-penetrant capabilities, combination therapy potential with KRAS-inhibitors, and analysis of MTAP truncations impact. Additionally, the company will present findings on tumor regression in FOCAD-deleted cancers through HBS1L/PELO complex disruption.
According to Dr. Adam Crystal, President of Research and Development, the data demonstrates the potential of their molecules as standalone treatments and combination partners in MTAP-deleted cancers, suggesting future development opportunities.
Tango Therapeutics (NASDAQ: TNGX) ha annunciato l'accettazione di cinque abstract per presentazioni poster al AACR Annual Meeting 2025 a Chicago. Le presentazioni metteranno in evidenza dati preclinici focalizzati sui loro programmi di inibitori di PRMT5, in particolare TNG456 e TNG462, progettati per il trattamento dei tumori con delezione di MTAP.
Tra i punti salienti della ricerca ci sono la valutazione della penetrazione del farmaco nel sistema nervoso centrale, le capacità di penetrazione cerebrale, il potenziale della terapia combinata con inibitori di KRAS e l'analisi dell'impatto delle troncature di MTAP. Inoltre, l'azienda presenterà risultati sulla regressione tumorale nei tumori con delezione di FOCAD attraverso la disruzione del complesso HBS1L/PELO.
Secondo il Dr. Adam Crystal, Presidente della Ricerca e Sviluppo, i dati dimostrano il potenziale delle loro molecole come trattamenti autonomi e come partner in combinazione nei tumori con delezione di MTAP, suggerendo opportunità di sviluppo futuro.
Tango Therapeutics (NASDAQ: TNGX) anunció la aceptación de cinco resúmenes para presentación en cartel en la AACR Annual Meeting 2025 en Chicago. Las presentaciones mostrarán datos preclínicos centrados en sus programas de inhibidores de PRMT5, en particular TNG456 y TNG462, diseñados para tratar cánceres con deleción de MTAP.
Los aspectos destacados de la investigación incluyen la evaluación de la penetración de medicamentos en el sistema nervioso central, las capacidades de penetración cerebral, el potencial de terapia combinada con inhibidores de KRAS y el análisis del impacto de las truncaciones de MTAP. Además, la compañía presentará hallazgos sobre la regresión tumoral en cánceres con deleción de FOCAD a través de la disrupción del complejo HBS1L/PELO.
Según el Dr. Adam Crystal, Presidente de Investigación y Desarrollo, los datos demuestran el potencial de sus moléculas como tratamientos independientes y como socios en combinación en cánceres con deleción de MTAP, sugiriendo oportunidades de desarrollo futuro.
탱고 테라퓨틱스 (NASDAQ: TNGX)는 시카고에서 열리는 AACR 연례 회의 2025에서 포스터 발표를 위한 다섯 개 초록이 수락되었다고 발표했습니다. 발표 내용은 MTAP 결실 암 치료를 위해 설계된 PRMT5 억제제 프로그램, 특히 TNG456 및 TNG462에 초점을 맞춘 전임상 데이터를 보여줄 것입니다.
연구의 주요 내용으로는 CNS 약물 침투 평가, 뇌 침투 능력, KRAS 억제제와의 병용 요법 가능성, MTAP 절단의 영향 분석 등이 포함됩니다. 또한, 회사는 HBS1L/PELO 복합체의 파괴를 통해 FOCAD 결실 암에서의 종양 퇴축에 대한 발견도 발표할 것입니다.
아담 크리스탈 박사, 연구 및 개발 사장은 이 데이터가 MTAP 결실 암에서 독립적인 치료제 및 병용 파트너로서 그들의 분자의 잠재력을 보여주며, 향후 개발 기회를 제안한다고 말했습니다.
Tango Therapeutics (NASDAQ: TNGX) a annoncé l'acceptation de cinq résumés pour des présentations par affiche lors de la AACR Annual Meeting 2025 à Chicago. Les présentations mettront en avant des données précliniques axées sur leurs programmes d'inhibiteurs de PRMT5, en particulier TNG456 et TNG462, conçus pour traiter les cancers avec délétion de MTAP.
Les points forts de la recherche incluent l'évaluation de la pénétration des médicaments dans le système nerveux central, les capacités de pénétration cérébrale, le potentiel de thérapie combinée avec des inhibiteurs de KRAS et l'analyse de l'impact des troncations de MTAP. De plus, la société présentera des résultats sur la régression tumorale dans les cancers avec délétion de FOCAD grâce à la disruption du complexe HBS1L/PELO.
Selon le Dr. Adam Crystal, Président de la Recherche et Développement, les données démontrent le potentiel de leurs molécules en tant que traitements autonomes et partenaires de combinaison dans les cancers avec délétion de MTAP, suggérant des opportunités de développement futures.
Tango Therapeutics (NASDAQ: TNGX) gab die Annahme von fünf Abstracts für Posterpräsentationen auf dem AACR Annual Meeting 2025 in Chicago bekannt. Die Präsentationen werden präklinische Daten vorstellen, die sich auf ihre PRMT5-Inhibitoren-Programme konzentrieren, insbesondere auf TNG456 und TNG462, die zur Behandlung von MTAP-deletierten Krebserkrankungen entwickelt wurden.
Zu den Forschungshighlights gehören die Bewertung der CNS-Arzneidurchdringung, die Fähigkeit zur Gehirndurchdringung, das Potenzial von Kombinationstherapien mit KRAS-Inhibitoren und die Analyse der Auswirkungen von MTAP-Truncationen. Darüber hinaus wird das Unternehmen Erkenntnisse über die Tumorreduktion bei FOCAD-deletierten Krebserkrankungen durch die Störung des HBS1L/PELO-Komplexes präsentieren.
Laut Dr. Adam Crystal, Präsident der Forschung und Entwicklung, zeigen die Daten das Potenzial ihrer Moleküle als eigenständige Behandlungen und Kombinationspartner bei MTAP-deletierten Krebserkrankungen und deuten auf zukünftige Entwicklungsmöglichkeiten hin.
- Development of brain-penetrant cancer treatment candidates TNG456 and TNG462
- Strong efficacy demonstrated in combination therapy studies
- Multiple drug candidates advancing in preclinical development
- All data still in preclinical stage, requiring further clinical validation
- No clinical efficacy data available yet
Insights
Tango's AACR presentations offer valuable validation for their synthetic lethality platform, particularly highlighting two key PRMT5 inhibitors targeting MTAP-deleted cancers. The most significant advancement appears to be TNG456, their next-generation, brain-penetrant inhibitor, which could potentially address the substantial unmet need in CNS tumors harboring MTAP deletions - a historically challenging area for targeted therapies.
Their preclinical data demonstrating TNG462's efficacy in combination with existing targeted therapies, particularly KRAS inhibitors, represents a strategically sound approach. Combination potential with established drug classes could accelerate development pathways and expand addressable patient populations beyond MTAP-deletion monotherapy.
The presentation on MTAP truncations' impact on clinical activity suggests Tango is working to identify optimal biomarkers for patient selection, which would be critical for clinical trial design and eventual commercialization strategy. Meanwhile, the research on HBS1L/PELO complex disruption in FOCAD-deleted cancers indicates pipeline diversification beyond their lead PRMT5 programs.
While these findings represent meaningful scientific progress that strengthens Tango's platform validation, investors should recognize these are still preclinical results that face the significant hurdle of clinical translation. For a company with a
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
“The data we are presenting at this year’s AACR meeting highlights important preclinical analyses of our PRMT5 programs that underscore the potential of these molecules as both standalone treatments and as key combination partners in MTAP-deleted cancers, including in combination with KRAS-inhibitors, paving the way for future development opportunities,” said Adam Crystal, MD, PhD, President of Research and Development.
Abstracts accepted for poster presentation
Title: Preclinical evaluation of CNS drug penetration of a novel series of MTAP-selective PRMT5 inhibitors including TNG456
Abstract #: 463
Session Title: Epigenetic Targets
Presenter: Alice Tsai, Ph.D., Executive Director, Tango Therapeutics
Date, Time: Sunday April 27, 2025, 2:00pm – 5:00pm CDT
Title: TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors with MTAP loss
Abstract #: 462
Session Title: Epigenetic Targets
Presenter: Kimberly Briggs, Ph.D., Director, Tango Therapeutics
Date, Time: Sunday April 27, 2025, 2:00pm – 5:00pm CDT
Title: TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrates strong efficacy in combination with clinically relevant targeted therapies in MTAP-null preclinical models
Abstract #: 2996
Session Title: Identification of Molecular Targets 1
Presenter: Minjie Zhang, Ph.D., Senior Director, Tango Therapeutics
Date, Time: Monday April 28, 2025, 2:00pm – 5:00pm CDT
Title: Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitors
Abstract #: 4608
Session Title: Molecular Diagnosis, Molecular Characterization and Theranostics of Tumors
Presenter: Kimberly Briggs, Ph.D., Director, Tango Therapeutics
Date, Time: Tuesday April 29, 2025, 9:00am – 12:00pm CDT
Title: Genetic and pharmacological disruption of the HBS1L/PELO complex impairs mRNA homeostasis and leads to in vivo tumor regressions in FOCAD-deleted cancers
Abstract #: 4252
Session Title: New and Emerging Cancer Drug Targets
Presenter: Hilary Nicholson, Ph.D., Principal Scientist, Tango Therapeutics
Date, Time: Tuesday April 29, 2025, 9:00am – 12:00pm CDT
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future operating performance and goals, the anticipated benefits of therapies and combination therapies (that include a Tango pipeline product), as well as the expectations, beliefs and development objectives for Tango’s product pipeline and clinical trials. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”, “predict”, “designed,” “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: the potential of the Company’s PRMT5 molecules, as both standalone treatments and as key combination partners in MTAP-deleted cancers, including in combination with KRAS-inhibitors; the preclinical research of the Company’s PRMT5 inhibitors, as a monotherapy and in combination, and the expectation that they may pave the way for future development opportunities; and the expected timing of: (i) development candidate declaration for certain targets; (ii) initiating IND-enabling studies; (iii) filing INDs; (iv) clinical trial initiation, dose escalation and dose expansion (including for combination studies); (v) disclosing initial, interim, updated, additional and final clinical trial results (including for combination studies); and (vi) the expected benefits of the Company's development candidates and other product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the benefits of product candidates seen in preclinical tests and analyses may not be evident when tested in later preclinical studies or in clinical trials or when used in broader patient populations (if approved for commercial sale); Tango has limited experience conducting clinical trials (and does and will continue to rely on a third party to operate its clinical trials) and may not be able to commence its clinical trials (including opening clinical trial sites, dosing the first patient, and continued enrollment and dosing of an adequate number of clinical trial participants) when expected, may not be able to continue dosing, initiate dose escalation and/or dose expansion on anticipated timelines, and may not generate or report clinical trial results (including final, initial, interim, updated clinical trial results or additional safety and efficacy data and the establishment of proof-of-mechanism and proof-of-concept) in the anticipated timeframe (or at all); future clinical trial data releases may differ materially from initial or interim data from our current and future clinical trials; Tango’s pipeline products may not be safe and/or effective in humans; Tango has a limited operating history and has not generated any revenue to date from product sales, and may never become profitable; other companies may be able to identify and develop product candidates more quickly than the Company and commercially introduce the product prior to the Company; the Company’s proprietary discovery platform is novel and may not identify any synthetic lethal targets for future development; the Company may not be able to identify development candidates on the schedule it anticipates due to technical, financial or other reasons; the Company may not be able to file INDs for development candidates on time, or at all, due to technical or financial reasons or otherwise; the Company may utilize cash resources more quickly than anticipated; Tango will need to raise capital in the future and if we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our development programs or future commercialization efforts (which may delay filing of INDs, dosing patients, initiation of dose expansion, reporting clinical trial results and filing new drug applications); Tango’s approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products; the Company may be unable to advance our preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or we may experience significant delays in doing so as a result of factors beyond Tango’s control; the Company may not be able to realize the benefits of orphan drug or Fast Track designation (and such designations may not advance any anticipated approval timelines); the expected benefits of our product candidates in patients as single agents and/or in combination may not be realized; the Company may experience delays or difficulties in the initiation, enrollment, or dosing of patients in clinical trials or the announcement of clinical trial results, Tango may not identify or discover additional product candidates or may expend limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; the Company’s product candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could, among other things, delay or prevent regulatory approval; our dependence on one or a limited number third parties for conducting clinical trials and producing drug substance and drug product (including drug substance, which is currently sole sourced); government regulation may negatively impact the Company’s business, including the potential approval of the BIOSECURE Act; and our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates or the scope of intellectual property protection obtained is not sufficiently broad. Additional information concerning risks, uncertainties and assumptions can be found in Tango’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as supplemented and/or modified by its most recent Quarterly Report on Form 10-Q. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
FAQ
What preclinical data will Tango Therapeutics (TNGX) present at AACR 2025?
When and where will Tango Therapeutics (TNGX) present at AACR 2025?
What are the key features of Tango Therapeutics' TNG456 drug candidate?
How does TNG462 perform in combination therapy according to TNGX's preclinical studies?
